214287-90-8
Chemical Structure
DPC 963
- CAS No.: 214287-90-8
- Formula:C14H9F5N2O
- Molecular Weight:316.23
IUPAC Name: (S)-4-(cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one
InChIKey: QCNJQJJFXFJVCX-ZDUSSCGKSA-N
SMILES: FC(F)(F)[C@@]1(C2=C(F)C(F)=CC=C2NC(N1)=O)C#CC3CC3
Biological Activity: DPC-963 is an oral active non-nucleoside reverse transcriptase inhibitor with the IC50 of 18 nM. DPC-963 can be used for study of HIV[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DPC 963 | DPC-963 is an oral active non-nucleoside reverse transcriptase inhibitor with the IC50 of 18 nM. DPC-963 can be used for study of HIV. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Corbett JW, et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999;43(12):2893-2897. [Content Brief]
- [2]. Corbett JW, et al. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem. 2000;43(10):2019-2030. [Content Brief]
Keywords